Technology Bundle ID
TAB-3574

Target JAK2/IL11-mediated Pathway by LY2784544 to Treat Platinum Drug Resistant Ovarian Cancer

Applications
Linked ID
E-130-2017-0
Lead Inventors
Wenge Zhu (George Washington University)
Co-Inventors
Wei Sun (NCATS)
Wei Zheng (NCATS)
Wei Zhou (George Washington University)
ICs
This technology includes a novel approach targeting the IL-11/JAK2 signaling pathway to treat platinum drug resistant ovarian cancer, as well as other cancers that are resistant to platinum-based agents. Platinum drugs have been widely used to treat many cancers, including ovarian cancer, but most patients become refractory to platinum drugs over time and ultimately succumb to the diseases due to resistance. Employing a drug repurposing screen using cisplatin resistant ovarian cancer cells, we found that a combination treatment of a platinum drug with LY2784544 (JAK2 inhibitor) effectively overcomes platinum drug resistance in ovarian cancer and other tumors (i.e., testicular, bladder, head and neck, esophageal, small and non-small cell lung, breast, cervical, stomach and prostate). Since LY2784544 is related to the IL11 signaling pathway, the combination therapy of platinum drugs with the new anti-LI11 compounds is another new approach to treat platinum drug resistant ovarian cancer.
Commercial Applications
Treatment of platinum drug resistant ovarian cancer, as well as other cancers that are resistant to platinum-based agents.
Competitive Advantages
Targeting the IL-11/JAK2 signaling pathway is a novel alternative approach to treat platinum drug resistant ovarian cancer, as well as other cancers that are resistant to platinum-based agents.

Request More Info

Licensing Contact: